Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796412 | 0.84 | KMT2A (0.42) | KMT2ATP53POLBGAAMEN1 | |
| SCHEMBL16796443 | 0.84 | KDM4C (0.36) | MAPTGAAALDH1A1 | |
| SCHEMBL20753233 | 0.83 | MAPT (0.44) | KMT2AMAPTTDP1TP53POLB | |
| SCHEMBL22978601 | 0.82 | MAPT (0.47) | KMT2AMAPTTDP1TP53POLB | |
| SCHEMBL16796444 | 0.79 | — | — | |
| SCHEMBL19635920 | 0.78 | MAPT (0.48) | KMT2AMAPTTDP1TP53POLB | |
| SCHEMBL16807367 | 0.77 | KMT2A (0.38) | KMT2AMAPTTDP1TP53POLB | |
| SCHEMBL7218733 | 0.77 | ALDH1A1 (0.45) | KMT2APOLBGAAMEN1ALDH1A1 | |
| SCHEMBL16082701 | 0.76 | KDM4E (0.43) | KMT2ATP53POLBGAAALDH1A1 | |
| SCHEMBL16807019 | 0.74 | KMT2A (0.41) | KMT2ATP53POLBGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015089182-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 3344/4885MAPT 4863/4885TDP1 1261/4885 |
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | KMT2A 3053/4885MAPT 4869/4885TDP1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.